Abstract: A reconfigurable electronic device including a housing reconfigurable between an unfolded configuration and a folded configuration about a folding axis, comprising: a first housing portion having a first surface and at least one camera disposed at the first surface, wherein the first surface is free of a display, a second housing portion hingeably coupled to the first housing portion about the folding axis. The device may include a connector disposed between the first and second housing portions, the connector comprising a motorized rotating-shaft assembly configured to effect coordinated rotation of the first and second housing portions about the folding axis between the unfolded configuration and the folded configuration, wherein, in the folded configuration, the second housing portion overlies at least part of the first surface to physically occlude the at least one camera.

Abstract: According to embodiments of the present disclosure, a method, an apparatus, a device, and a storage medium for providing content in an application are provided. In a method, a first-type interaction event between a user of an application and content provided in the application is received. Based on the first-type interaction event and an event model, a prediction of whether the user performs a second-type interaction event associated with the content is determined, the event model describing an association relationship between the first-type interaction event performed by the user and the second-type interaction event performed by the user. A provision action of providing the content in the application is adjusted based on the prediction. In this way, the prediction of the second-type interaction event may be determined in a more real-time and accurate manner, and the provision action may be adjusted based on the prediction.

Abstract: Embodiments of this application disclose a software test method, to improve test efficiency of scenario-based testing. The method in embodiments of this application includes the following: A computing device obtains an application programming interface API calling sequence on a cloud platform, where the API calling sequence includes API calling records sorted by time on the cloud platform, and the API calling records include names of APIs called by the computing device at different times; generates a spatial-temporal graph based on the API calling sequence, where the spatial-temporal graph includes a calling relationship between a plurality of APIs and calling times; identifies, based on the spatial-temporal graph, at least one user scenario corresponding to the API calling sequence, and generates a test case corresponding to the at least one user scenario; and performs software testing based on the test case.

Abstract: A magnetic resonance imaging (MRI) system that includes a support member and permanent magnets. The permanent magnets are positioned within the support member such that the permanent magnets are arranged along a single plane, which may be either linear or non-linear (e.g., curved), and vary in size (e.g., height and/or diameter).

Abstract: Provided is a method of using at least one peripheral device including an image sensor and at least one processor for operating a target device, including receiving a first input from a user associated with the target device indicative of a task to be performed by the target device; determining a first instruction for the target device to perform based on the first input; determining whether the first instruction includes displaying content associated with the task on the target device; in response to determining that the first instruction includes displaying content associated with the task on the target device, obtaining displayed content associated with the task on the target device; and determining a second instruction for the target device to perform based on a second input received from the user indicative of a reaction to the displayed content associated with the task on the target device.

Abstract: Chlorogenic acid is used in the preparation of a drug for treating and/or preventing ocular inflammation. Chlorogenic acid can significantly alleviate symptoms of uveitis and scleritis, and has good treatment effects on ocular inflammation.

Abstract: Chlorogenic acid is used in the preparation of a medicine for preventing or treating pain. The pain can be cancer pain, skeletal muscle pain and the like. A medicine for preventing or treating pain, the medicine being a pharmaceutical preparation prepared by using chlorogenic acid as an active ingredient and adding pharmaceutically acceptable auxiliary materials. Chlorogenic acid may effectively relieve cancer pain and bone joint pain, and may replace analgesic drugs such as opioids and non-steroidal anti-inflammatory drugs in treatment.

Abstract: Chlorogenic acid and/or coumaroylquinic acid are employed in preparation of drugs for treating squamous cell carcinoma. Chlorogenic acid or coumaroylquinic acid can effectively treat squamous cell carcinoma. A combination of chlorogenic acid and coumaroylquinic acid can also achieve effective treatment, can yield a synergistic effect, and has excellent application prospect.

Abstract: Chlorogenic acid is used in the preparation of a medicine for treating a central nervous system tumor. It is discovered that chlorogenic acid may effectively treat diffuse large B-cell lymphoma, which provides a new clinical treatment of central nervous system tumors, especially diffuse large B-cell lymphoma.

Abstract: A pharmaceutical composition includes chlorogenic acid and coumaroylquinic acid. It can be used for preparing a reversing agent for tumor multi-drug resistance and a PD-1/PD-L1 inhibitor. The combined use of chlorogenic acid and coumaroylquinic acid exhibits a synergistic effect, effectuating a good reversing effect on the drug resistance of a tumor cell strain that produces multi-drug resistance for chemotherapeutic drugs and immunotherapeutic drugs, which may effectively inhibit PD-1/PD-L1 expression in drug-resistant B16 melanoma and drug-resistant Lewis lung cancer mice transplantation tumor tissue, and may effectively proliferate CD4+T and CD8+T cells in drug-resistant B16 melanoma mice and Lewis lung cancer mice.

Abstract: A pharmaceutical composition contains chlorogenic acid and coumaroyl quinic acid. The combined use of chlorogenic acid and coumaroyl quinic acid at a certain ratio can generate a synergistic enhancing effect to effectively inhibit the growth of human kidney cancer cell strain A479, rat kidney cell strain RuCa, and rat transplanted tumor RuCa, providing a novel choice for clinical treatment of kidney cancer and having good market application prospects.

Abstract: Chlorogenic acid or compositions containing chlorogenic acid are used in preparation of a medicament for treating sarcoma. The chlorogenic acid composition includes chlorogenic acid and coumaroyl quinic acid, can effectively treat sarcoma, and has a better therapeutic effect than the chemotherapeutic medicament doxorubicin. The experimental results show that the combination of chlorogenic acid and coumaroylquinic acid can have a synergistic effect.

Abstract: A display method and apparatus, a wearable device, and a computer-readable storage medium. The method is applied to the wearable device. The wearable device comprises an inertial sensor and at least two screen display areas; when a user wears the wearable device, the screen display areas are not located on the same plane at the same time. The method comprises: obtaining a target action of a user by means of measurement data collected by the inertial sensor; determining the screen display area corresponding to a sight range of the user according to the target action of the user; and lighting the screen display area to display the current content.

Abstract: A pharmaceutical composition containing chlorogenic acid can be used in the preparation of a drug for treating the early Alzheimer's disease. In the pharmaceutical composition chlorogenic acid is used as a main active ingredient, and 3-coumaroylquinic acid is used as an auxiliary ingredient. The latter can effectively improve the therapeutic effect of chlorogenic acid for treating the early Alzheimer's disease.

Abstract: A pharmaceutical composition containing chlorogenic acid is used in the preparation of a medicament for treating pathologic jaundice. In the pharmaceutical composition, chlorogenic acid is used as a main active ingredient, and bifidobacteria and human milk oligosaccharides are used as auxiliary ingredients. The latter can effectively enhance the therapeutic effect of chlorogenic acid for treating pathologic jaundice, thereby reducing the amount thereof. The pharmaceutical composition can effectively reduce the contents of total bilirubin and indirect bilirubin in blood, and provides a new means and choice for pharmacotherapy of pathologic jaundice, especially hemolytic jaundice.

Abstract: Provided a method, an apparatus, a wearable device and a storage medium for audio playback, and relates to the fields of machine learning, deep learning, intelligent wearable, etc. The method includes: measured vital sign data of a user within a first time range is obtained; a vital sign prediction is performed based on the measured vital sign data within the first time range, to obtain predicted vital sign data of the user within a second time range after the first time range; one or more target audio parameters are determined based on the predicted vital sign data and user attribute information of the user; and matched target audio data is obtained based on the one or more target audio parameters.

Abstract: A pharmaceutical composition for treating hyperlipidemia and a preparation method therefor are provided. The pharmaceutical composition contains chlorogenic acid, vitamins, pharmaceutically acceptable excipients and optional microelements. The pharmaceutical composition for treating hyperlipidemia reduce can serum total cholesterol and serum triglyceride, and increase the content of high-density lipoproteins.

Abstract: Provided are a display method and apparatus, a smart wearable device, and a computer-readable storage medium, the display method being used on the smart wearable device, and the smart wearable device including at least two screen display regions and at least two corresponding audio collection units; when a user is wearing the smart wearable device, the screen display regions are not simultaneously in the same plane. The display method includes according to voice signals collected by all of the audio collection units, determining an audio collection unit nearest a sound source; turning on a screen display region corresponding to the audio collection unit nearest the sound source to display current content.

Abstract: A medicine for combined use in cancer treatment, comprising chlorogenic acid and a hormone drug which have unit preparations of the same or different specifications and which are administered either together or separately, as well as comprising a pharmaceutically acceptable carrier. The combined use of the chlorogenic acid and hormone drug achieves the effects of synergistic interaction, which thus overcome the defects of single drug treatment, such as a major toxic side effect and a poor treatment outcome and may reverse the drug resistance to hormone drugs and has good prospects for clinical application.

Abstract: An anti-tumor composition for nasal administration has chlorogenic acid as an active ingredient, with the addition of pharmaceutically acceptable excipients or auxiliary ingredients. The chlorogenic acid preparation can improve the bioavailability of chlorogenic acid for nasal administration, penetrate the blood-brain barrier, have a significant inhibitory effect on brain tumors and nasopharyngeal carcinoma, and possess a clinical application value.